Table 1 Comparison of clinical factors and outcome variables in patients with recurrent glioblastoma treated with different approaches
| Â | Salvage treatment | ||||
|---|---|---|---|---|---|
Characteristics | Re-irradiation | Re-surgery | Chemotherapy | Best supportive care | p Value |
(N= 15) | (N=6 ) | (N=37 ) | (N=25 ) | ||
Age (years) | Â | Â | Â | Â | Â |
Median | 51.5 | 65 | 66 | 66 | RT vs no-RT 0.002 |
Range | 41-73 | 55-73 | 49-72 | 55-79 | Â |
<60 years | 5 | 3 | 21 | 20 | Â |
<=60 years | 10 | 3 | 16 | 5 | 0.02 |
Gender, N0. (%) | Â | Â | Â | Â | Â |
Men | 11 (73%) | 4 (67%) | 22 (59%) | 9 (38%) | 0.33 |
Women | 4 (27%) | 2 (33%) | 15 (41%) | 16 (62%) | Â |
Primary Surgery, N0. (%) | Â | Â | Â | Â | Â |
Total | 11 (73%) | 4 (67%) | 18 (49%) | 10 (39%) | 0.18 |
Subtotal | 3 (20%) | 2 (33%) | 11 (30%) | 4 (15%) | Â |
Biopsy | 1 (7%) | 0 | 8 (21%) | 11 (46%) | Â |
Karnofsky performance status at diagnosis (%) | Â | Â | Â | Â | . |
Median | 90 | 90 | 90 | 90 | n.s |
Range | 80-100 | 80-100 | 70-100 | 70-100 | Â |
RPA classification at diagnosis, N0. (%) | Â | Â | Â | Â | Â |
IV | 9 (60%) | 5 (83%) | 18 (50%) | 13 (54%) | Â |
V | 5 (33%) | 1 (17%) | 8 (20%) | 6 (23%) | Â |
VI | 1 (7%) | 0 | 11 (30%) | 6 (23%) | Â |
MGMT Methylation, N0. (%) | Â | Â | Â | Â | Â |
Yes | 7 (47%) | 4 (67%) | 12 (33%) | 10 (38%) | 0.47 |
No | 5 (33%) | 2 (33%) | 20 (54%) | 13 (54%) | Â |
Unknown | 3 (20%) | 0 | 5 (13%) | 2 (8%) | Â |
Primary Tumor location, N0 (%) | Â | Â | Â | Â | Â |
Frontal | 3 (20%) | 3 (50%) | 12 (34%) | 10 (39%) | 0.72 |
Temporal | 4 (27%) | 3 (50%) | 13 (35%) | 6 (23%) | Â |
Parietal | 6 (40%) | 0 | 8 (21%) | 6 (23%) | Â |
Occipital | 2 (13%) | 0 | 4 (10%) | 3 (15%) | Â |
Primary Tumor side, N0 (%) | Â | Â | Â | Â | Â |
Left | 8 (53%) | 4 (67%) | 20 (54%) | 14 (54%) | 0.96 |
Right | 7 (47%) | 2 (33%) | 17 (46%) | 11 (46%) | Â |
Type of recurrence, N0 (%) | Â | Â | Â | Â | Â |
In-field | 9 (60%) | 5 (83%) | 32 (86%) | 19 (77%) | Â |
Out-field | 6 (40%) | 1 (17%) | 5 (14%) | 6 (23%) | 0.19 |
Karnofsky performance status at recurrence (%) | Â | Â | Â | Â | Â |
Median | 90 | 90 | 80 | 80 | n.s. |
Range | 80-100 | 80-100 | 70-100 | 70-100 | Â |
Median OS from primary diagnosis (months) | 33 | 17 | 17 | 9.9 | RT vs no-RT 0.001 |
Cox regression analysis OR coef f-p | 0.102 | 0.268 | 0.331 | 1 | Â |
1.4e-07 | 0.016 | 0.00018 | - | Â | |
Time between primary therapy and salvage treatment | Â | Â | Â | Â | Â |
Median (months) | 10.8 | 10 | 8 | 5 | 0.003 |
Range (months) | 6-54 | 7-24 | 7-21 | 2-11 | Â |
Median OS from recurrence(months) | 9.5 | 5.5 | 5.5 | 2.5 | RT vs no-RT 0.001 |
Cox regression analysisOR coef f-p | 0.16 | 0.34 | 0.33 | 1 | Â |
0.000016 | 0.052 | 0.0015 | - | Â | |